Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    • Cash ban, Brexit weigh heavy; expect normalcy in Q4: Wockhardt

    • See double-digit sales growth across markets in FY17: Wockhardt

    • Hopeful of US FDA issue getting resolved soon: Wockhardt

    • Wockhardt reports disappointing Q3 earnings

    • Pharma companies revenues to rise 12% in Q3: Anand Rathi

    • Wockhardt Q1 PAT may dip 27% at Rs 296 cr: Emkay

      Emkay Equity Advisory expects Wockhardt to report a 11.5 percent degrowth quarter-on-quarter (fall of 26.7 percent year-on-year) in net profit at Rs 296.3 crore.

    • IIFL gung-ho on pharma, expects Sun to beat Q4 estimates

      Bino Pathiparampil of IIFL, says that stock like Sun Pharma has been beating estimates for last eight quarters and the same performance is likely to continue in this quarter. Ranbaxy‘s business has been worsening over the last 2-3 quarters and one can‘t expect major improvement to happen in the base business.

    • PAT boost on low debt-equity, high interest: Wockhardt

      Wockhardt chairman Habil Khorakiwala explains to CNBC-TV18's Archana Shukla that the PAT will get a boost on low debt-equity ratio, and high interest rates.

    • Earnings watch: Which pharma co is in pink of its health?

      In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.

    • Niche products, US sales boost Wockhardt: Finquest

      Anand Bagaria, senior research analyst, Finquest explains to CNBC-TV18 that pharma major Wockhardt has posted a strong run in terms of a stock performance as well as fundamentals and gained over 250% from the start of the year.

    • Wockhardt Q4 net sales up 32% at Rs 1,241 cr

      Pharmaceutical company Wockhardt has reported a consolidated net loss of Rs 192 crore for the fourth quarter of FY12 as against profit of Rs 162 crore in the corresponding quarter of last fiscal, due to exceptional loss of Rs 450 crore during the quarter.

    • Wockhardt sees healthy 30% margins in FY12

      In an interview to CNBC-TV18, Habil Khorakiwala, chariman of the Wockhardt Group said the EBITDA growth for FY12 is likely to be at 72%, while the margins are seen at 30%.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347